Murphy Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Murphy Capital Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$3.34M	Sell	52,341 -534	-1%	-$33.9K	0.46%	53
2022 Q1	$3.42M	Sell	52,875 -1,350	-2%	-$85.6K	0.4%	60
2021 Q4	$3.61M	Sell	54,225 -1,890	-3%	-$120K	0.39%	59
2021 Q3	$3.42M	Sell	56,115 -675	-1%	-$42.9K	0.4%	60
2021 Q2	$3.52M	Sell	56,790 -495	-0.9%	-$30.1K	0.4%	60
2021 Q1	$3.39M	Sell	57,285 -255	-0.4%	-$15.4K	0.43%	56
2020 Q4	$3.44M	Sell	57,540 -1,185	-2%	-$67.5K	0.46%	54
2020 Q3	$3.2M	Sell	58,725 -1,155	-2%	-$62.3K	0.46%	54
2020 Q2	$3.07M	Sell	59,880 -735	-1%	-$37K	0.49%	53
2020 Q1	$2.72M	Sell	60,615 -8,280	-12%	-$418K	0.52%	50
2019 Q4	$3.68M	Sell	68,895 -2,955	-4%	-$146K	0.52%	53
2019 Q3	$3.35M	Sell	71,850 -1,635	-2%	-$78.3K	0.5%	55
2019 Q2	$3.69M	Sell	73,485 -1,383	-2%	-$68.4K	0.55%	51
2019 Q1	$3.84M	Sell	74,868 -4,560	-6%	-$227K	0.59%	50
2018 Q4	$3.73M	Sell	79,428 -1,635	-2%	-$83.8K	0.63%	46
2018 Q3	$4.54M	Sell	81,063 -438	-0.5%	-$23.9K	0.63%	47
2018 Q2	$4.11M	Sell	81,501 -1,494	-2%	-$74.1K	0.59%	49
2018 Q1	$4.08M	Sell	82,995 -1,476	-2%	-$75.8K	0.58%	52
2017 Q4	$4.35M	Sell	84,471 -1,065	-1%	-$54.7K	0.6%	50
2017 Q3	$4.46M	Sell	85,536 -1,668	-2%	-$85.6K	0.64%	48
2017 Q2	$4.51M	Sell	87,204 -2,250	-3%	-$114K	0.66%	47
2017 Q1	$4.5M	Sell	89,454 -4,875	-5%	-$241K	0.67%	47
2016 Q4	$4.45M	Sell	94,329 -6,732	-7%	-$319K	0.7%	43
2016 Q3	$5.03M	Sell	101,061 -4,881	-5%	-$248K	0.78%	40
2016 Q2	$5.1M	Sell	105,942 -12,711	-11%	-$605K	0.79%	37
2016 Q1	$5.42M	Sell	118,653 -7,200	-6%	-$337K	0.85%	34
2015 Q4	$6.78M	Sell	125,853 -372	-0.3%	-$19.6K	1.03%	27
2015 Q3	$6.23M	Sell	126,225 -960	-0.8%	-$55K	1.03%	27
2015 Q2	$7.41M	Sell	127,185 -2,580	-2%	-$151K	1.11%	22
2015 Q1	$7.46M	Buy	129,765 +2,130	+2%	+$117K	1.1%	23
2014 Q4	$6.44M	Sell	127,635 -705	-0.5%	-$34.4K	0.98%	30
2014 Q3	$6M	Buy	128,340 +660	+0.5%	+$29.8K	0.94%	31
2014 Q2	$5.75M	Sell	127,680 -315	-0.2%	-$13.5K	0.91%	30
2014 Q1	$5.41M	Sell	127,995 -4,278	-3%	-$179K	0.91%	29
2013 Q4	$5.21M	Sell	132,273 -285	-0.2%	-$10.7K	0.91%	30
2013 Q3	$4.7M	Sell	132,558 -4,362	-3%	-$154K	0.89%	28
2013 Q2	$4.55M	Buy	+136,920	New	+$4.55M	0.93%	28

Other funds holding IHE

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EWG Elevate Roseville, California $320M AUM 18.11% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RWP

RWA Wealth Partners Newton, Massachusetts $9.14B AUM 16.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Murphy Capital Management's IHE Position: Q2 2022 in Review

Murphy Capital Management reduced its iShares US Pharmaceuticals ETF (IHE) stake by 1% in Q2 2022, selling an estimated $33.9K and leaving 52,341 shares worth $3.34M. The position accounts for 0.46% of the portfolio, ranked #53.

Murphy Capital Management first reported a position in IHE in Q2 2013 and has held it in 37 quarters since. The position peaked at $7.46M in Q1 2015. 125 funds tracked by Wall St. Rank hold IHE as of Q2 2022.

Murphy Capital Management held 52,341 shares of iShares US Pharmaceuticals ETF worth $3.34M as of Q2 2022.
Murphy Capital Management sold 534 iShares US Pharmaceuticals ETF shares in Q2 2022, an estimated $33.9K.
iShares US Pharmaceuticals ETF made up 0.46% of Murphy Capital Management's portfolio in Q2 2022, its #53 holding.
Murphy Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 37 quarters since.
Murphy Capital Management's iShares US Pharmaceuticals ETF position peaked at $7.46M in Q1 2015.
125 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2022.

Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.